Central Asia’s First Biothreat Research Lab to Play Threat-Reduction Role

Rachel Oswald, Global Security Newswire
Aug. 9, 2013, 9:02 a.m.

SE­MEY, Kaza­kh­stan — A state-of-the-art med­ic­al re­search labor­at­ory is un­der con­struc­tion in a sub­urb of Al­maty, Kaza­kh­stan’s busi­ness cap­it­al, us­ing U.S. funds aimed at help­ing re­ori­ent former bio­lo­gic­al weapons-re­lated re­search un­der the So­viet Uni­on to peace­ful pub­lic health uses, ac­cord­ing to of­fi­cials in­volved with the pro­ject.

When it opens in 2015, the Cent­ral Ref­er­ence Labor­at­ory is ex­pec­ted to fo­cus on some of the world’s most dan­ger­ous emer­ging patho­gens with sup­port from the Nunn-Lugar Co­oper­at­ive Threat Re­duc­tion Pro­gram, draw­ing off of years of U.S. and Kaza­kh­stani joint co­oper­a­tion.

“We’re go­ing to have here the most up-to-date equip­ment,” said B.B. Atshabar, dir­ect­or of the Kaza­kh­stan Sci­entif­ic Cen­ter for Quar­ant­ine and Zo­onot­ic Dis­eases, speak­ing through a trans­lat­or to a group of U.S. journ­al­ists who vis­ited the con­struc­tion site of the new labor­at­ory on Tues­day.

Once fin­ished, the planned 87,000 square-foot labor­at­ory is slated to be the first of its kind in Cent­ral Asia to in­clude re­search areas that meet in­ter­na­tion­ally re­cog­nized Biosafety Level-3 stand­ards, which in­volve spe­cial en­gin­eer­ing, design and staff-train­ing pro­to­cols in­ten­ded to min­im­ize the risks of work­ing with po­ten­tially deadly dis­ease agents, such as an­thrax and plague. Yet more of the lab space, though, will be de­voted to Biosafety Level-2 work in­volving the study of patho­gens that pose mod­er­ate health haz­ards.

“The ul­ti­mate goal of the labor­at­ory will be its in­ter­na­tion­al ac­cred­it­a­tion,” Atshabar said. “The res­ults that will be achieved in this labor­at­ory will be open to all of the world” to util­ize, he said.

The fo­cus of work at the fu­ture fa­cil­ity will be on de­vel­op­ing im­proved dia­gnost­ic tools and coun­ter­meas­ures for patho­gens that af­fect both hu­mans and an­im­als. The labor­at­ory is also ex­pec­ted to aid neigh­bor­ing Cent­ral Asi­an states in dia­gnos­ing and con­trolling the spread of new dis­ease strains, he said.

An­thrax and plague are en­dem­ic to Kaza­kh­stan and have been pub­lic health con­cerns here for some time. Kaza­kh­stani sci­ent­ists have de­veloped con­sid­er­able ex­pert­ise in­to these patho­gens but their re­search up un­til now has taken place in loc­al labor­at­or­ies that lack the in­ter­na­tion­ally re­cog­nized BSL-3 stand­ards, ac­cord­ing to Atshabar.

Un­der the So­viet Uni­on, “there wasn’t really a no­tion of peer-re­viewed sci­ence or trans­par­ency at all. Most of what they did was very tightly clas­si­fied and they had a lot of over­lap with the mil­it­ary,” said Phil Starling, the pro­gram dir­ect­or for sci­ence en­gage­ment at CRDF Glob­al, a non­profit that works on Co­oper­at­ive Threat Re­duc­tion pro­grams in Kaza­kh­stan and else­where un­der con­tract with the U.S. gov­ern­ment. Stand­ard prac­tice at that time was for sci­ent­ists in Kaza­kh­stan identi­fy­ing new strains of plague, for ex­ample, to send samples back to Mo­scow where they would be ex­amined and stud­ied spe­cific­ally for po­ten­tial ap­plic­a­tion as bio­lo­gic­al weapons, he said.

Kaza­kh­stan be­came an in­de­pend­ent na­tion in Decem­ber 1991, fol­low­ing the dis­sol­u­tion of the So­viet Uni­on.

Through the CTR pro­gram, the United States has worked to steer Kaza­kh­stani sci­ent­ists with a back­ground in dis­eases such as plague and an­thrax to non­mil­it­ary re­search that is trans­par­ent and pub­lished un­der the prin­ciples of glob­al sci­ence, said Starling. He was in­ter­viewed by phone in the United States late last month.

“A big part of the re­ori­ent­a­tion was in­tro­du­cing [Kaza­kh­stani sci­ent­ists] to the prin­ciples of west­ern [glob­al] sci­ence,” he said. “You get fund­ing based on the rig­or of your re­search and the valid­ity of your re­search, not ne­ces­sar­ily oth­er polit­ic­al pri­or­it­ies,” he said.

An­oth­er as­pect of CTR work in Kaza­kh­stan is find­ing em­ploy­ment for those sci­ent­ists with back­grounds in bio­lo­gic­al-weapon re­lated re­search, so that they will not be temp­ted to sell their ex­pert­ise to ter­ror­ists or rogue na­tions.

“We’ve done our best to em­ploy these people who have this know­ledge. It’s one of these chal­lenges that you can­not erase this know­ledge from someone’s mind,” said Lt. Col. Charles Carlton, dir­ect­or of the U.S. De­fense Threat Re­duc­tion Of­fice in Kaza­kh­stan.

“I do think that through our ef­forts, through U.S. fund­ing, Kaza­kh­stani fund­ing, we are do­ing our best to em­ploy these people,” he said on Tues­day to re­port­ers on a trip or­gan­ized by the In­ter­na­tion­al Re­port­ing Pro­ject.

Fund­ing for the $100 mil­lion con­struc­tion of the Cent­ral Ref­er­ence Labor­at­ory is com­ing en­tirely from the United States. Once it is up and run­ning, Wash­ing­ton each year will gradu­ally re­duce the amount of funds it provides to Kaza­kh­stan to op­er­ate the sci­entif­ic fa­cil­ity, un­til the gov­ern­ment in As­tana is fully un­der­writ­ing the labor­at­ory, Carlton said.

The CRL fa­cil­ity will con­tain 5,400 square feet of BSL-3 re­search space, ac­cord­ing to Dan Erbach, the site con­struc­tion man­ager for AE­COM, the com­pany build­ing the fa­cil­ity.

The U.S. gov­ern­ment is also provid­ing ap­prox­im­ately $5.6 mil­lion to build a sep­ar­ate site fea­tur­ing BSL-3 labor­at­ory space in the vil­lage of Otar in Kaza­kh­stan’s Zhambyl­skaya re­gion. The fa­cil­ity is in­ten­ded to provide an early warn­ing of any new dis­ease out­breaks that oc­cur in the re­gion and is in­ten­ded to com­ple­ment rather than du­plic­ate the work done at the Cent­ral Ref­er­ence Labor­at­ory in Al­maty, Carlton said. The Otar fa­cil­ity is ex­pec­ted to be com­pleted next April.

What We're Following See More »
STAFF PICKS
When It Comes to Mining Asteroids, Technology Is Only the First Problem
20 hours ago
WHY WE CARE

Foreign Policy takes a look at the future of mining the estimated "100,000 near-Earth objects—including asteroids and comets—in the neighborhood of our planet. Some of these NEOs, as they’re called, are small. Others are substantial and potentially packed full of water and various important minerals, such as nickel, cobalt, and iron. One day, advocates believe, those objects will be tapped by variations on the equipment used in the coal mines of Kentucky or in the diamond mines of Africa. And for immense gain: According to industry experts, the contents of a single asteroid could be worth trillions of dollars." But the technology to get us there is only the first step. Experts say "a multinational body might emerge" to manage rights to NEOs, as well as a body of law, including an international court.

Source:
STAFF PICKS
Obama Reflects on His Economic Record
21 hours ago
WHY WE CARE

Not to be outdone by Jeffrey Goldberg's recent piece in The Atlantic about President Obama's foreign policy, the New York Times Magazine checks in with a longread on the president's economic legacy. In it, Obama is cognizant that the economic reality--73 straight months of growth--isn't matched by public perceptions. Some of that, he says, is due to a constant drumbeat from the right that "that denies any progress." But he also accepts some blame himself. “I mean, the truth of the matter is that if we had been able to more effectively communicate all the steps we had taken to the swing voter,” he said, “then we might have maintained a majority in the House or the Senate.”

Source:
STAFF PICKS
Reagan Families, Allies Lash Out at Will Ferrell
22 hours ago
WHY WE CARE

Ronald Reagan's children and political allies took to the media and Twitter this week to chide funnyman Will Ferrell for his plans to play a dementia-addled Reagan in his second term in a new comedy entitled Reagan. In an open letter, Reagan's daughter Patti Davis tells Ferrell, who's also a producer on the movie, “Perhaps for your comedy you would like to visit some dementia facilities. I have—I didn’t find anything comedic there, and my hope would be that if you’re a decent human being, you wouldn’t either.” Michael Reagan, the president's son, tweeted, "What an Outrag....Alzheimers is not joke...It kills..You should be ashamed all of you." And former Rep. Joe Walsh called it an example of "Hollywood taking a shot at conservatives again."

Source:
PEAK CONFIDENCE
Clinton No Longer Running Primary Ads
1 days ago
WHY WE CARE

In a sign that she’s ready to put a longer-than-ex­pec­ted primary battle be­hind her, former Sec­ret­ary of State Hil­lary Clin­ton (D) is no longer go­ing on the air in up­com­ing primary states. “Team Clin­ton hasn’t spent a single cent in … Cali­for­nia, In­di­ana, Ken­tucky, Ore­gon and West Vir­gin­ia, while” Sen. Bernie Sanders’ (I-VT) “cam­paign has spent a little more than $1 mil­lion in those same states.” Meanwhile, Sen. Jeff Merkley (D-OR), Sanders’ "lone back­er in the Sen­ate, said the can­did­ate should end his pres­id­en­tial cam­paign if he’s los­ing to Hil­lary Clin­ton after the primary sea­son con­cludes in June, break­ing sharply with the can­did­ate who is vow­ing to take his in­sur­gent bid to the party con­ven­tion in Phil­adelphia.”

Source:
CITIZENS UNITED PT. 2?
Movie Based on ‘Clinton Cash’ to Debut at Cannes
1 days ago
WHY WE CARE

The team behind the bestselling "Clinton Cash"—author Peter Schweizer and Breitbart's Stephen Bannon—is turning the book into a movie that will have its U.S. premiere just before the Democratic National Convention this summer. The film will get its global debut "next month in Cannes, France, during the Cannes Film Festival. (The movie is not a part of the festival, but will be shown at a screening arranged for distributors)." Bloomberg has a trailer up, pointing out that it's "less Ken Burns than Jerry Bruckheimer, featuring blood-drenched money, radical madrassas, and ominous footage of the Clintons."

Source:
×